Comparative Pharmacology
Head-to-head clinical analysis: MICROGESTIN 1 20 versus PIRMELLA 7 7 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICROGESTIN 1 20 versus PIRMELLA 7 7 7.
MICROGESTIN 1/20 vs PIRMELLA 7/7/7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing estrogen (ethinyl estradiol) and progestin (norethindrone acetate). Inhibits gonadotropin secretion (FSH, LH) via negative feedback, preventing ovulation. Also causes cervical mucus thickening and endometrial thinning.
Pirmelevir is a selective inhibitor of the hepatitis C virus (HCV) NS5A protein, essential for viral replication and assembly. It disrupts the double-membrane vesicles where HCV RNA replication occurs.
One tablet (norethindrone acetate 1 mg / ethinyl estradiol 20 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
PIRMELLA 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.035 mg and norgestimate 0.180/0.215/0.250 mg in a triphasic regimen. One tablet daily for 28 days, with 7 inactive tablets.
None Documented
None Documented
Norethindrone: 5.2-12.8 hours (mean ~8 hours); Ethinyl estradiol: 7-20 hours (mean ~13 hours); hepatic impairment prolongs.
Terminal elimination half-life: 8-10 hours. Clinically, steady-state reached in 2-3 days.
Renal: 40% as metabolites, 20% as glucuronide and sulfate conjugates; Fecal: 35%; Biliary: <5%.
Renal: 70% unchanged; fecal: 30% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive